NCT00257491View on ClinicalTrials.gov

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Hypertension
Interventions
DRUG

Telmisartan

DRUG

Telmisartan/HCTZ

Trial Locations (1)

200025

Shanghai Ruijin Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00257491 - Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension | Biotech Hunter | Biotech Hunter